

# MEDICAMEN Biotech Limited



Regd. Office :  
1506, Chiranjiv Tower,  
43, Nehru Place, New Delhi-110019  
CIN No. : L74899DL1993PLC056594.

Tel. : 011 - 47589500, 41608929  
Tel. : 011 - 21800032  
Fax : 011 - 26213081  
Web : www.medicamen.com

Ref: BSE/PRE ALL/2017-2018

Date: 14<sup>th</sup> December, 2017

## The BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
**Mumbai – 400001**

**Company Number: 531146**

**Sub. : Outcomes of the Board Meeting held on 14.12.2017**

Dear Sir,

This is to inform you that the Board of Directors in its meeting held today commenced at 2.00 P.M. and concluded at 3.00 P.M, has transacted the following businesses subject to approval of the shareholders of the Company:

1. Approval to the Issue & Allot 324000 Equity Shares at a price of Rs.618/- per share (including a premium of Rs.608/- each), in accordance with the SEBI (ICDR) Regulations, 2009 on Preferential Allotment basis to a promoter group and non promoter group/ Investors as follows:

Sr. No	Name of Allottee	Category	No. of Shares
1	M/s Shivalik Rasayan Ltd.	Promoter	76000
2	M/s Kim Ginnerup APS (Denmark)	Public	50000
3	Ashish Jain	Public	5000
4	Deepesh Jain	Public	5000
5	Jinendra Kumar Jain	Public	25000
6	Ravikant Chowdhary	Public	25000
7	Gyan Chand Bhaiya	Public	12000
8	Kailash Bhaiya	Public	12000
9	M Shikar HUF	Public	17000
10	Daksha V Jain	Public	12000
11	Dhirajkumar Babulal Jain	Public	8000
12	Vardhaman Hemkumar	Public	12000
13	Aditya Anil Gaggar	Public	5000
14	Anirudh Anil Gaggar	Public	5000
15	C Rajalakshmi	Public	17000
16	P Srikanth	Public	12000
17	Sri Kedar Properties Pvt. Ltd.	Public	16000
18	Rishi Tulsyan	Public	10000
	<b>Total</b>		<b>324000</b>



2. Company will use the proceeds from the above said preferential issue of Equity Shares for setting up a new Oncology facility at Haridwar.
3. Calling of an Extraordinary General Meeting, of the Company in relation to the Preferential Issue as aforesaid on 12<sup>th</sup> January, 2018.

This is for your information and records.



Kindly acknowledge the receipt.

Thanking You.

Yours Faithfully  
For Medicamen Biotech Ltd.

  
(Kiran)  
Company Secretary





**Medicamen Biotech Limited**

---

**[www.medicamen.com](http://www.medicamen.com)**



# Safe Harbour

**Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward looking statements. MEDICAMEN Biotech Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.**

# Company overview

Medicamen Biotech is a pharmaceutical company in joint venture and equity participation with **PHARMADANICA A/S Denmark**



*A sign of co-operation*


1993

Year of incorporation



2 plants

Ultra modern facilities in Bhiwadi and Haridwar



+ 250

Employees




25


Countries catering to globally



# Journey till date



# Bhiwadi Plant



**Location:** Rajasthan  
**Covered area:** 120,000 square feet  
**Products:** Tablets, Capsules, Dry Syrups, ORS, Liquid Orals

## Facility divided into six separate blocks



**Beta Lactum Block**

- ▶ Tablets
- ▶ Capsules
- ▶ Dry syrups



**Non-Beta Lactum Block**

- ▶ Tablets
- ▶ Capsules
- ▶ Dry syrups



**ORS and Liquid orals Block**



**Warehouse and Quality Assurance /Quality Control Block**




**Formulation Development, Analytical and Chemical Research Development**  
– Near completion



**Finished Goods Store Block**  
– Near completion



# Haridwar Plant




## Unit I

Location: Utrakhand  
Covered area: 32,000 square feet

Facility has a single two storied unit



Non Betalactum Tablets  
Non Betalactum Capsules  
Liquid orals  
External Ointments



## Unit II

Location: Utrakhand  
Covered area: 35,000 square feet  
**Proposed oncology  
manufacturing facility**
























Unit II



# Plant Photographs



# INTERNATIONAL PLANTS APPROVALS

	Brazil	ANVISA		Namibia	NMRC
	Bhutan	BRA		Nigeria	NAFDAC
	Cameroon	MPH		PAHO	PAHO
	Congo	MPH		Phillipines	BFAD
	Ethiopia	DACA		South Sudan	MOH
	Ghana	FDB		Sri Lanka	CDDA
	Ivory Coast	MOH		Tanzania	TFDA
	Kenya	MHPPB		Uganda	NDA
	Lesotho	NDSO		Vietnam	DA
	Malawi	MPPB		Zambia	MPB
				Zimbabwe	MCAZ

# Entry in oncology segment



# Why oncology

Oncology is the largest contributor in pharmaceutical market\* with a share of more than 10% in 2016


## Global pharmaceutical market

- Global expenditure on medical treatment expected to reach US\$1.5 trillion by 2021.

## Global oncology market


- Growth has been driven by oncology therapeutics will reach US\$147-177 billion by 2021.

Global pharmaceutical market  
(prescription & OTC drugs in US\$ billion)



Source: EvaluatePharma

Global market of oncology therapeutics  
and supportive care drugs (in US\$ billion)



Source: IMS Institute


Note: \*Pharmaceutical market includes prescription and over the counter (OTC) drugs



# Top 10 therapy areas

Oncology is expected to remain the largest segment in 2022 with a forecasted annual growth of 15%, reaching US\$192.2b

## Top 10 therapy areas in 2022, market share and sales growth




Bubble size represents sales in US\$ billion in 2022

Source: EvaluatePharma

# Medicamen intends to enter the oncology segment with purchase of a new facility


Acquired a new facility adjoining the existing Haridwar plant to exclusively manufacture oncology therapeutics



Propose to manufacture **20 products** of which **5 are top 10 global oncology drugs** of 2016



Focused markets include **European Union market, Latin America and Rest of the world**



To manufacture **tablet, capsules, injectable, lyophilize** in the following batch size:

- Tablets and capsules: 25 kg
- Injectable and lyophilizes: 50 litres



# Top 10 oncology products in 2016

## Medicamen plans to manufacture 5 of the top 10 drugs




Source: IGEA Hub

# Rationale for oncology product selection

1

Products having global sales more than US\$1b



3

Substantial value expectation in times to come



2

Easy market entry with no IP /Patent hurdle



4

Therapeutic domain dominance in specific cancer area





# Profit and loss statement (Actual)

Rs. in Lakhs

Particulars	1H FY18 (April-Sept 17)	FY17	FY16
Turnover	5391.35	8245.57	6,727.59
Other Income	110.51	30.66	70.02
Expenditure	4637.18	7,144.93	6,226.60
<b>EBITDA</b>	<b>864.68</b>	<b>1131.31</b>	<b>571.01</b>
EBITDA Margin	14.04%	13.72%	8.48%
Interest	115.41	303.20	310.14
Depreciation	99.58	192.23	189.69
<b>Profit/(Loss) before Tax (PBT)</b>	<b>649.69</b>	<b>635.87</b>	<b>71.18</b>
PBT Margin	12.52%	7.71%	1.05%
Tax Expenses	131.20	119.86	23.09
<b>Profit/(Loss) after Tax (PAT)</b>	<b>518.49</b>	<b>516.01</b>	<b>48.09</b>
PAT Margin	9.61%	6.25%	0.71%
<b>EPS (Rs.)</b>	<b>4.42</b>	<b>4.95</b>	<b>0.48</b>



# Thank you

**MB** Medicamen Biotech Limited

**Registered Office:**

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500

Fax: 011-26213081

E-mail: [info@medicamen.com](mailto:info@medicamen.com)

Website: [www.medicamen.com](http://www.medicamen.com)